{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-013237","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.121087+00:00","generated_at":"2026-06-17T18:42:36.970066+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVROBIO reports Q4 net loss $25.0M, full-year 2022 loss $105.9M; cash $92.6M","bullets":["Net loss of $25.0M in Q4 2022 vs $28.2M in Q4 2021; full year loss $105.9M vs $119.1M.","R&D expenses $18.1M (Q4) and $72.2M (FY); G&A expenses $7.1M (Q4) and $33.2M (FY).","Cash and equivalents $92.6M as of Dec 31, 2022, down from $189.6M a year earlier; expects to fund operations into Q1 2024.","Plan to initiate registrational global Phase 2/3 trial (Guard3) for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.","Collaborator-sponsored Phase 1/2 trial for cystinosis completed dosing; late-stage activities planned H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-013237","json":"https://secwatch.observer/filing/0001140361-23-013237.json","markdown":"https://secwatch.observer/filing/0001140361-23-013237.md","text":"https://secwatch.observer/filing/0001140361-23-013237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/0001140361-23-013237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/brhc10050093_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:42:36.970066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf1e9f1d23b39da8f71333433321fda76e3d146e","claim":"Tectonic Therapeutic, Inc. reported financial results for the three months and year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/0001140361-23-013237-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}